Misonix Incorporated Extends Contract with Mentor Corporation with Plans to Increase Share of Ultrasound Assisted Liposuction Market

FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (Nasdaq: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, announced today that it has extended its agreement with the Mentor Corporation (NYSE: MNT) for domestic sales of its ultrasound assisted liposuction (“UAL”) product, the LySonix® 3000. Under the terms of the new contract, Mentor has agreed to minimum purchase order provisions for the LySonix 3000 for a term of one year, beginning September 30, 2007, and successive annual renewals upon mutual agreement by the companies.

Back to news